NCT04592549View on ClinicalTrials.gov

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions
SARS-CoV-2
Interventions
DRUG

ADM03820

ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies

OTHER

Placebo

Placebo

Trial Locations (2)

27103

PMG Research of Winston-Salem, LLC, Winston-Salem

78209

ICON Early Phase Services, LLC, San Antonio

Sponsors
All Listed Sponsors
collaborator

Enabling Biotechnologies (EB)

UNKNOWN

lead

Alachua Government Services, Inc.

INDUSTRY